Literature DB >> 10663633

In vitro antioxidant properties of amifostine (WR-2721, Ethyol).

F Marzatico1, C Porta, M Moroni, L Bertorelli, E Borasio, N Finotti, O Pansarasa, L Castagna.   

Abstract

PURPOSE: Amifostine (WR-2721), a phosphorylated aminothiol pro-drug which is an analogue of cysteamine, is a selective cytoprotective agent for normal tissues from the toxicities associated with chemotherapy and irradiation. Despite a growing number of reports strongly supporting amifostine's clinical efficacy, few authors have focused on the biochemical basis of amifostine's antioxidant activity.
METHODS: We report on amifostine's free-radical scavenging activity against superoxide (O(2;(-))), hydroxyl (OH(-)) and lipoperoxyl radicals in an in vitro model, using pure chemical systems. Amifostine was dephosphorylated to its active metabolite, WR-1065, by adding 10% non-heat-inactivated serum; different amifostine concentrations (1, 10, 50, 100 microM and 200 microM) and pH conditions (pH 5, 7.4 and 9) were tested.
RESULTS: Independent of the concentration, amifostine exhibited no major activity against O(2;(-)) ions, neither did any pH variations in the experimental model provide any scavenger effects of the drug against O(2;(-)) radicals. On the other hand, the protective effect of amifostine against OH(-) radicals was confirmed, yielding an EC(50) of 255 microM at pH 7.4 and 230 microM at pH 5. Finally, amifostine exhibited scavenging activity against spontaneous lipoperoxidation, but no apparent antioxidant effect on iron ascorbate-induced lipoperoxidation.
CONCLUSIONS: With this in vitro study, we are able to confirm the scavenging activity of the chemo- and radioprotector amifostine, whose activity seems to be particularly important from a biological point of view, since it is exerted mainly against highly reactive OH(-).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10663633     DOI: 10.1007/s002800050026

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  The radioprotective agent WR1065 protects cells from radiation damage by regulating the activity of the Tip60 acetyltransferase.

Authors:  Ye Xu; Kalindi Parmar; Fengxia Du; Brendan D Price; Yingli Sun
Journal:  Int J Biochem Mol Biol       Date:  2011-10-20

2.  Administration of rat acute-phase protein α(2)-macroglobulin before total-body irradiation initiates cytoprotective mechanisms in the liver.

Authors:  Desanka Bogojević; Goran Poznanović; Nevena Grdović; Ilijana Grigorov; Melita Vidaković; Svetlana Dinić; Mirjana Mihailović
Journal:  Radiat Environ Biophys       Date:  2010-09-17       Impact factor: 1.925

3.  The effect of amifostine, a cytoprotective agent, on paraquat toxicity in mice.

Authors:  Brandon K Wills; Steven Aks; Gerry E Maloney; James Rhee; Rhonda Brand; Marin Sekosan
Journal:  J Med Toxicol       Date:  2007-03

4.  WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability.

Authors:  Jaroslaw Dziegielewski; Janet E Baulch; Wilfried Goetz; Mitchell C Coleman; Douglas R Spitz; Jeffrey S Murley; David J Grdina; William F Morgan
Journal:  Free Radic Biol Med       Date:  2008-09-18       Impact factor: 7.376

5.  Amifostine (WR2721) confers DNA protection to in vivo cisplatin-treated murine peripheral blood leukocytes.

Authors:  E A Prieto González; A G Fuchs; González S Sánchez
Journal:  Dose Response       Date:  2009-06-11       Impact factor: 2.658

6.  Evaluation of protective effect of amifostine on dacarbazine induced genotoxicity.

Authors:  M Etebari; A Jafarian-Dehkordi; V Lame
Journal:  Res Pharm Sci       Date:  2015 Jan-Feb

7.  Amifostine alleviates radiation-induced lethal small bowel damage via promotion of 14-3-3σ-mediated nuclear p53 accumulation.

Authors:  Eng-Yen Huang; Feng-Sheng Wang; Yu-Min Chen; Yi-Fan Chen; Chung-Chi Wang; I-Hui Lin; Yu-Jie Huang; Kuender D Yang
Journal:  Oncotarget       Date:  2014-10-30

8.  High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets.

Authors:  Isabella Russo; Michela Viretto; Cristina Barale; Luigi Mattiello; Gabriella Doronzo; Andrea Pagliarino; Franco Cavalot; Mariella Trovati; Giovanni Anfossi
Journal:  Diabetes       Date:  2012-07-26       Impact factor: 9.461

Review 9.  Fullerenols as a new therapeutic approach in nanomedicine.

Authors:  Jacek Grebowski; Paulina Kazmierska; Anita Krokosz
Journal:  Biomed Res Int       Date:  2013-10-07       Impact factor: 3.411

10.  The Efficacy of Amifostine against Multiple-Dose Doxorubicin-Induced Toxicity in Rats.

Authors:  Vesna Jaćević; Viktorija Dragojević-Simić; Željka Tatomirović; Silva Dobrić; Dubravko Bokonjić; Aleksandra Kovačević; Eugenie Nepovimova; Martin Vališ; Kamil Kuča
Journal:  Int J Mol Sci       Date:  2018-08-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.